SVIDENCE

Simplifying Progress

BioPAT[®] Trace – Glucose and Lactate Online Monitoring and Control



Agenda


1. Introduction to Process Analytical Technology (PAT)

2. Working principle of BioPAT[®] Trace

3. Applications & process control of BioPAT® Trace



How does PAT improve a bioprocess?




Source: Svea Grieb, Kai Touw, Dan Kopec, 'What's beyond the bioprocess automation starting line', The Medicine Maker, July 2019

SVITCITAS

How does PAT improve a bioprocess?

Traditional process without PAT



Problems / Risks


Process with PAT

- Contamination risk through sampling
- Sample might change after removal from the reactor
- Reactor volume is lost
- Manual steps are prone to operator errors
- Up to 3h time delay between measurement and response
- No sampling over night / on weekends \geq 24|7 monitoring and control

- Manual sampling not required
- Sample is not removed
- Reactor volume is unaffected
- Automation eliminates risk of operator errors
- ➢ Faster measurement results through data integration



Sartorius has a comprehensive PAT portfolio



Agenda

1. Introduction to Process Analytical Technology (PAT)


2. Working principle of BioPAT® Trace

3. Applications & process control of BioPAT® Trace





BioPAT® Trace is an automated online glucose and lactate sensor




BioPAT® Trace:

- > glucose and lactate biosensor based on glucose oxidase and lactate oxidase
- > 1 molecule of glucose generates 2 electrons. Electrons give an amperometric signal (current).
- > The measured current is proportional to the amount of glucose.

14 SARTURIUS

BioPAT® Trace uses a dialysis probe to measure glucose outside the bioreactor without removing a sample from the bioreactor




Key features


Automatic calibration throughout the process: Several available calibration standards ensure highest resolution at your concentration of interest

SVILCIEVES

- Fully closed SU system with specially designed FlexBoy bags
- SU tubeset easily removed and replaced after a run

BioPAT® Trace uses a dialysis probe to measure glucose outside the bioreactor without removing a sample from the bioreactor





probe inserted into the STR through KPC port

Trace software and hardware

SVILCIEVES

Key technology: Trace dialysis probe

- no volume reduction
- fast response time (up to 30 measurements / hour)
- independent of media composition and viscosity

Agenda

1. Introduction to Process Analytical Technology (PAT)


2. Working principle of BioPAT® Trace

3. Applications & process control of BioPAT® Trace



BioPAT® Trace can be integrated in many Sartorius bioreactors

- Biostat® STR: multi-use probe integration via aseptic port for all sizes (50L-2000L)
- Biostat[®] RM: integration via bypass module (2L-200L)
- Biostat[®] B with Universel (benchtop): multi-use probe integration, up to 4 parallel systems can be connected to the BioPAT[®] MultiTrace
- Biostat[®] C and D-DCU (stainless steel): multi-use probe integration



BioPAT[®] Trace in Biostat[®] STR






BioPAT[®] Trace in Biostat[®] RM

BioPAT[®] MultiTrace in Biostat[®] Univessel



An integrated glucose/lactate sensor can automatically control glucose concentration




Automated glucose control

- > prevents overfeeding and starvation of cells
- ➢ affects glycosylation and glycation
- frees up operators
- reduces risks of manual sampling



BioPAT[®] Trace can perform different glucose control strategies




Glucose control with BioPAT® Trace:


- Consistently good correlation to offline measurement
- Can be set to continuously control the glucose level
- Can be set to trigger bolus additions




Low glucose control has significant positive impact on product titer and quality in high-lactate processes



 low glucose control (<0.5g/l) maintains low lactate levels



 low lactate levels lead to higher peak cell density and longer cell viability



 low glucose control results in titer increase (32% overall titer increase)

SVILCIEVS

The culture time could be extended by 2 days


Benefits of glucose control below 1g/l:

- Ionger cultivations
- higher viable cell densities
- \succ increased product titers
- \succ homogenious glycation

Requirements for low glucose control:

- measurement of both glucose and lactate
- high sampling frequency: min. 30min
- no sample removal required
- \blacktriangleright easy PID control implementation

Low glucose control with BioPAT® Trace for higher process output and more consistent product quality







- near constant level control possible
- data shows that a glucose control at 1.4 g/L leads to high lactate levels, whereas 0.9 g/L glucose control can significantly reduce the lactate level
- Iow glucose levels lead to low lactate levels
- positive effects on peak VCD, cultivation time and titer
- narrow glucose control leads to defined glycosylation profiles of the product



Controlling glucose can reduce unwanted glycation



- The extent of glycation* on the monoclonal antibody rhuMAb depends on the amount of glucose increase per feed event (low = 2g/L, medium = 3g/L, high = 6g/L)
- Addition of high amounts of glucose at once (typical bolus feed) are unfavorable




- The extent of glycation depends on the feeding strategy
- The more constant the glucose concentration, the lower the extent of glycation
- Continuously keeping the glucose concentration at 3 g/L (fully continuous glc feed) gives 3-times less glycation than a bolus feed strategy (medium glucose feed)

*Protein glycation is a non-enzymatic glycosylation that can occur to proteins in the human body. Glycation can also occur to recombinant antibodies during cell culture, which generates structural heterogeneity in the product and is therefore unwanted. It is different from glycosylation, which is the enzyme-mediated, site-specific addition of sugar to a protein.

SVISCIEVS

'...These results show that we can **control glycation** of secreted proteins by controlling the glucose concentration in the cell culture. ...'

The glucose concentration & feeding strategy affects glycosylation




- A Cellca-2 process producing a mAB was run with the conventional time-based **bolus**, **high glucose** feed protocol with BioPAT Trace monitoring glucose and lactate conncentration (top graph)
- And using BioPAT Trace to continuously control a low glucose concentration of 0.8 g/L (bottom graph)



 The different feeding strategies did not affect the cell growth, viability or protein titer, as expected for a low lactate process, such as Cellca-2.

continuous	1.74 g/L
bolus	1.67 g/L
protein titer	

These results show that **we can control glycosylation** of secreted proteins by controlling the glucose concentration in the cell culture.



- The analysis of the mAB glycosylation showed a shift in the galactose glycosylation
- The proportion of monogalactosylated (G1) structures & digalactosylated structures(G2) increased significantly

SVILOTXVS

BioPAT® Trace is widely accepted in the industry





Svea Cheeseman, PhD Product Manager PAT Mobile +44 7971 372168 Svea.Cheeseman@sartorius.com

SVIDUR